CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Sandoz Inc.

1:13-cv-01507

Overview

Case Number 1:13-cv-01507
Filing Date 2013-08-29
Status Terminated
Termination Date 2014-10-31
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Defendant

Sandoz Inc. Operating Company

Represented By

2 Attorneys Listed

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Plaintiff

Sanofi-Aventis U.S. LLC Operating Company

Represented By

2 Attorneys Listed

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Chad S.C. Stover

Barnes & Thornburg LLP

Tel: +1 (302) 300-3474

1000 N. West Street, Suite 1500, Wilmington, DE 19801

Genzyme Corporation NPE (Individual / Inventor)

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Kurt W. Rohde

Email: rohdek@mbhb.com

Jeremy E. Noe

Email: noe@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Chad S.C. Stover

Barnes & Thornburg LLP

Tel: +1 (302) 300-3474

1000 N. West Street, Suite 1500, Wilmington, DE 19801

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 2 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (2 found):
U.S. Courts: 2
U.S. District Court 2016-06-29
1:16-cv-00540

Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-08-29
1:13-cv-01508

Genzyme Corporation v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
USRE42152
Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
Filed: 1992-12-16
Issued: 2011-02-15
Expired (Term Ended) +2185d PTA
Expires: 2018-12-10
US7897590
Methods to mobilize progenitor/stem cells
Filed: 2007-08-20
Issued: 2011-03-01
Expired (Term Ended)
Expires: 2024-11-16
US6987102
Methods to mobilize progenitor/stem cells
Filed: 2002-07-30
Issued: 2006-01-17
Expired (Term Ended) +357d PTA
Expires: 2023-07-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+2185 days) / Cellect Scrutiny β€” Over 2185 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed against Sandoz Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1358716.) - filed by Genzyme Corporation, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(mdb) (Entered: 08/30/2013)

Entry #1 • 2013-08-29
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mdb) (Entered: 08/30/2013)

Entry #2 • 2013-08-29
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/31/13. Date of Expiration of Patent: See Form.Thirty Month Stay Deadline: 1/31/2016. (mdb) (Entered: 08/30/2013)

Entry #3 • 2013-08-29
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US RE42,152 E; US 7,897,590 B2; US 6,987,102 B2;. (mdb) (Entered: 08/30/2013)

Entry #4 • 2013-08-29
1

Disclosure Statement pursuant to Rule 7.1 filed by Genzyme Corporation, Sanofi-Aventis U.S. LLC identifying Corporate Parent Aventis Pharmaceuticals Inc., Corporate Parent Sanofi-Synthelabo Inc. for Sanofi-Aventis U.S. LLC; Corporate Parent Aventis Inc., Other Affiliate Sanofi-Aventis U.S. LLC for Genzyme Corporation. (mdb) (Entered: 08/30/2013)

Entry #5 • 2013-08-29
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc